UBS Reiterates Buy Rating on Insmed (INSM) Into Q3 Earnings

October 8, 2026 9:33 AM

UBS analyst Ashwani Verma reiterated a Buy rating and $172.00 price target on Insmed (NASDAQ: INSM).The analyst commented, "Heading into ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found